Search results: Sage Journals

Restricted accessCase reportFirst published March, 2015

Extramedullary Breast Relapse of Acute Lymphoblastic Leukemia Controlled with a Second Allogeneic/Autologous Hematopoietic Cell Transplant

Amy B. Houghtelin, Lisa M. Kopp, Luz Pelayo-Katsanis [...]

Journal of Adolescent and Young Adult Oncology

Restricted accessResearch articleFirst published August, 1985

Failure of Second-Line Therapy to Modify Survival in Relapsed Squamous Cell Carcinoma of the Head and Neck

Marco Merlano, Andrea Grimaldi, Luigina Bonelli [...]

Tumori Journal

Restricted accessResearch articleFirst published May, 2018

Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis

Johannes Lorscheider, Pascal Benkert, Carmen Lienert [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published April, 2017

The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study

Ye An Kim, Sun Wook Cho, Hoon Sung Choi [...]

Thyroid®

Open accessResearch articleFirst published July, 2020

Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study

Oscar Fernández, Guillermo Izquierdo, Eduardo Aguera [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Restricted accessCase reportFirst published December, 2019

Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with central nervous system disease

Jason Chen, Dat Ngo, Joseph Rosenthal

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published November, 2016

Evolution of the Healthcare Expenditure in Italy and Effects of Fingolimod Increased Prescribing in Second Line Treatment of Relapsing-Remitting Multiple Sclerosis

Matteo Ruggeri, Andrea Aiello, Anna D'Ausilio [...]

Global & Regional Health Technology Assessment: Italian;Northern Europe and Spanish

Restricted accessResearch articleFirst published June, 2011

Efficacy and Safety of a Second Adalimumab Treatment Cycle in Psoriasis Patients who Relapsed after Adalimumab Discontinuation or Dosage Reduction: A Double-Blind,Randomized,Placebo-Controlled Trial

Amir Larian, Jason J. Emer, Kenneth Gordon [...]

Journal of Psoriasis and Psoriatic Arthritis®

Free accessResearch articleFirst published December, 2018

First-generation versus second-generation long-acting injectable antipsychotic drugs and time to relapse

James M. Stone, Simon Roux, David Taylor [...]

Therapeutic Advances in Psychopharmacology

Restricted accessResearch articleFirst published April, 2019

Topotecan/carboplatin regimen for refractory/recurrent rhabdomyosarcoma in children: Report from the AIEOP Soft Tissue Sarcoma Committee

Alessia Compostella, Maria Carmen Affinita, Michela Casanova [...]

Tumori Journal

Restricted accessCase reportFirst published March, 2015

Extramedullary Breast Relapse of Acute Lymphoblastic Leukemia Controlled with a Second Allogeneic/Autologous Hematopoietic Cell Transplant

Amy B. Houghtelin, Lisa M. Kopp, Luz Pelayo-Katsanis [...]

Journal of Adolescent and Young Adult Oncology

Restricted accessResearch articleFirst published August, 1985

Failure of Second-Line Therapy to Modify Survival in Relapsed Squamous Cell Carcinoma of the Head and Neck

Marco Merlano, Andrea Grimaldi, Luigina Bonelli [...]

Tumori Journal

Restricted accessResearch articleFirst published May, 2018

Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis

Johannes Lorscheider, Pascal Benkert, Carmen Lienert [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published April, 2017

The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study

Ye An Kim, Sun Wook Cho, Hoon Sung Choi [...]

Thyroid®

Open accessResearch articleFirst published July, 2020

Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study

Oscar Fernández, Guillermo Izquierdo, Eduardo Aguera [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Restricted accessCase reportFirst published December, 2019

Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with central nervous system disease

Jason Chen, Dat Ngo, Joseph Rosenthal

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published November, 2016

Evolution of the Healthcare Expenditure in Italy and Effects of Fingolimod Increased Prescribing in Second Line Treatment of Relapsing-Remitting Multiple Sclerosis

Matteo Ruggeri, Andrea Aiello, Anna D'Ausilio [...]

Global & Regional Health Technology Assessment: Italian;Northern Europe and Spanish

Restricted accessResearch articleFirst published June, 2011

Efficacy and Safety of a Second Adalimumab Treatment Cycle in Psoriasis Patients who Relapsed after Adalimumab Discontinuation or Dosage Reduction: A Double-Blind,Randomized,Placebo-Controlled Trial

Amir Larian, Jason J. Emer, Kenneth Gordon [...]

Journal of Psoriasis and Psoriatic Arthritis®

Free accessResearch articleFirst published December, 2018

First-generation versus second-generation long-acting injectable antipsychotic drugs and time to relapse

James M. Stone, Simon Roux, David Taylor [...]

Therapeutic Advances in Psychopharmacology

Restricted accessResearch articleFirst published April, 2019

Topotecan/carboplatin regimen for refractory/recurrent rhabdomyosarcoma in children: Report from the AIEOP Soft Tissue Sarcoma Committee

Alessia Compostella, Maria Carmen Affinita, Michela Casanova [...]

Tumori Journal